---
schema_version: "secwatch.filing_event.v1"
accession: "0001809519-24-000213"
form_type: "8-K"
ticker: "GDRX"
cik: "0001809519"
company_name: "GoodRx Holdings, Inc."
filed_at: "2024-12-16T23:59:59+00:00"
generated_at: "2026-05-29T03:04:17.782660+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# GoodRx appoints Wendy Barnes as CEO and President, effective Jan 1, 2025

## Summary
- Wendy Barnes named CEO/President, succeeding interim CEO Scott Wagner; also elected Class I director.
- Base salary of $825,000, target bonus 100% of salary, and a $550,000 signing bonus.
- Equity grants: $9M RSU, $9M option, and $2M additional RSU, vesting over time.
- Severance: 12-18 months base salary plus COBRA for 18 months, with accelerated vesting on change of control.
- Barnes previously CEO of RxBenefits and President of Express Scripts; holds biochemistry degree.

## SEC filing metadata
- accession: 0001809519-24-000213
- form_type: 8-K
- ticker: GDRX
- cik: 0001809519
- company_name: GoodRx Holdings, Inc.
- filed_at: 2024-12-16T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1809519/000180951924000213/0001809519-24-000213-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1809519/000180951924000213/gdrx-20241212.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001809519-24-000213
- JSON: https://secwatch.observer/filing/0001809519-24-000213.json
- Plain text: https://secwatch.observer/filing/0001809519-24-000213.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.